Highlight
Summary
About the Role
About You
- Health Care Professional degree preferred (e.g., RN/BSN/MSN, NP, PharmD) or a Bachelor of Science Degree in Life Sciences with relevant experience.
- Minimum of 8+ years management experience in the pharmaceutical industry for Associate Director or 10+ years for Director in drug safety & pharmacovigilance operations.
- Experience with FDA/EMA regulations and ICH guidance governing pharmacovigilance.
- Strong verbal and written communication skills.
- Master's degree in a relevant field.
- Five years of experience working with and providing oversight to PV vendors.
- Experience in preparation and review of data outputs for aggregate safety report generation.
- Knowledge of pharmacovigilance databases and MedDRA coding.
Benefits
- Base salary range of $171k–$243k USD, with potential for higher compensation for exceptional candidates.
- Comprehensive benefits package including medical, dental, vision, and life insurance.
- Employee Assistance Program and travel insurance.
- Retirement savings programs with company matching contributions.
- Vacation, personal days, sick days, and an end-of-year company shutdown.
- Tuition Assistance program for advanced degrees.
Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.